Last updated on July 2019

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Brief description of study

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).

Clinical Study Identifier: NCT03711162

Find a site near you

Start Over

Pulmonary Associates

Phoenix, AZ United States
  Connect »

National Jewish Health

Denver, CO United States
  Connect »

Tulane Medical Center

New Orleans, LA United States
  Connect »

Minnesota Lung Center

Minneapolis, MN United States
  Connect »

Creighton University

Omaha, NE United States
  Connect »

PulmonIx LLC

Greensboro, NC United States
  Connect »

The Oregon Clinic

Portland, OR United States
  Connect »

University of Wisconsin

Madison, WI United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »

Lung Research Qld

Chermside, Australia
  Connect »

Mayo Clinic Arizona - PPDS

Scottsdale, AZ United States
  Connect »

University of Utah Medical Care

Salt Lake City, UT United States
  Connect »

Mayo Clinic - PPDS

Rochester, MN United States
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Thorax Klinik

Heidelberg, Germany
  Connect »

Nottingham City Hospital

Nottingham, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.